Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group

NCT01901133 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics of MDV3100
Healthy Subjects
Kidney Diseases

Interventions

DRUG: MDV3100

Sponsor

Astellas Pharma Europe B.V.

Collaborators

[object Object]